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A reassessment of risk associated with dietary intake of 
ochratoxin A based on a lifetime exposure model
Lois A� Haighton, Barry S� Lynch, Bernadene A� Magnuson, and Earle R� Nestmann
Cantox Health Sciences International, An Intertek Company 
Abstract
Mycotoxins, such as ochratoxin A (OTA), can occur from fungal growth on foods. OTA is considered a possible risk factor 
for adverse renal effects in humans based on renal tumors in male rats. For risk mitigation, Health Canada proposed 
maximum limits (MLs) for OTA based largely on a comparative risk assessment conducted by Health Canada (Kuiper-
Goodman et al., 2010), in which analytical data of OTA in foods were used to determine the possible impact adopting 
MLs may have on OTA risks. The EU MLs were used for comparison and resultant risk was determined based on age–sex 
strata groups. These data were reevaluated here to determine comparative risk on a lifetime basis instead of age strata. 
Also, as there is scientific disagreement over the mechanism of OTA-induced renal tumors, mechanistic data were 
revisited. On a lifetime basis, risks associated with dietary exposure were found to be negligible, even without MLs, 
with dietary exposures to OTA three to four orders of magnitude below the pivotal animal LOAEL and the TD05. Our 
review of the mechanistic data supported a threshold-based mechanism as the most plausible. In particular, OTA was 
negative in genotoxicity assays with the highest specificity and levels of DNA adducts were very low and not typical of 
genotoxic carcinogens. In conclusion, OTA exposures from Canadian foods do not present a significant cancer risk.
Keywords:  Ochratoxin A (OTA), risk assessment, mechanisms, nephropathy, renal tumors, margin of exposure, 
threshold, genotoxicity, maximum limits
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introduction
Mycotoxins,  fungal  metabolites  resulting  from  fungal 
growth during food production and storage, can occur 
as natural contaminants in many foods, including those 
produced  in  or  imported  into  Canada�  Ochratoxin  A 
(OTA) is one such mycotoxin of potential concern relat-
ing to the documented association of OTA with rodent 
renal tumors, in particular among male rats, and with 
organ toxicity in pigs� Food commodities that are suscep-
tible to OTA contamination include wheat, oats, and rice, 
and other food products such as grapes, raisins, wine, 
corn, soy, coffee, and beer� Humans who typically con-
sume these foods (essentially all consumers) would be 
expected to have some exposure to OTA� Given its natural 
origin, pervasiveness at low levels and chemical stability, 
it is not possible to entirely eradicate OTA from the diet�
For  contaminants  that  may  pose  a  health  concern, 
risk-assessment  practices  may  be  used  to  determine 
a standard based on a dose or exposure that should be 
without appreciable risk to consumers� Risk assessment 
is  a  multistep  process  in  which  an  exposure  assess-
ment  and  hazard  assessment  are  typically  conducted 
independently, and the results of these assessments are 
compared to provide an estimation of risk� In assessing 
exposures to contaminants from the diet, a quantitative 
estimate of dietary intake can be determined from con-
centration  data  of  the  contaminants  in  foods  coupled 
with  food  intake  survey  data�  The  hazard  assessment 
involves the evaluation of toxicology data which may be 
obtained from animal and/or human studies to define the 
inherent toxicity of a substance� Determining the dose-
response curve of a contaminant is a component of the 
hazard assessment and the results can be used to derive 
a level of dietary intake that should not be associated 
with adverse effects in humans� The dose-response curve 
should  be  determined  for  the  most  sensitive  adverse 
effect that is considered to be mechanistically relevant to 
humans� The results of the exposure assessment can be 
compared to this dose to characterize the probability of 
adverse effects�
OTA and other mycotoxins are just one category of 
contaminants  that  may  commonly  be  found  in  foods� 
Other  chemical  contaminants  that  may  be  found  in 
foods and/or drinking water include heavy metals (e�g� 
lead, mercury, arsenic), residual pesticides, animal drug 
residues,  and  persistent  environmental  contaminants 
such as dioxins and polychlorinated biphenyls� Further 
to these are food-processing agent residues, food con-
tact material migrants, contaminants formed during the 
cooking of food, indirect food additives, as well as a wide 
array of naturally occurring mutagens and carcinogens 
that are normal constituents of foods� For some of these 
contaminants,  chemical-specific  maximum  concentra-
tions or residue limits have been established� These may 
be  adopted  as  a  voluntary  or  regulatory  standard  for 
specific food commodities or products� Deriving a maxi-
mum limit or standard may be based on health concerns 
or, if the ability to reduce the contaminant is diminished 
by  technological  limitations,  principles  of  “as  low  as 
reasonably achievable/practicable” (ALARA or ALARP) 
may be adhered to instead� In most other situations, the 
implementation  of  Good  Agricultural  Practices  (GAP) 
and Good Manufacturing Practices (GMP) are counted 
on to ensure that food products are of high quality and 
do not present a health risk�
However, stringent standards implemented for con-
taminants  such  as  mycotoxins  that  can  be  controlled 
through GAP and GMP could result in a greater frequency 
of  noncompliance  and  possible  food  product  deten-
tions and recalls, but may have little impact on reducing 
health risks� Wu (2004) conducted a risk assessment and 
analysis of the economic impacts versus health benefits 
that may be expected from tighter global regulation of 
fumonisins  and  aflatoxins�  The  author’s  findings  were 
that economic losses from the adoption of more stringent 
standards for these mycotoxins than those of the United 
States for agricultural producers would be in excess of 
100  million  dollars  and  would  be  unlikely  to  improve 
health significantly�
In contrast, adopting standards to prevent unlawful 
practices, such as adding melamine to infant formula to 
show a falsely higher protein content, are of benefit to 
protecting health� Therefore, in deriving standards, the 
ultimate aim should be to achieve optimal voluntary or 
regulatory maximum limits for human safety, which at 
the same time do not become technical barriers to trade 
or impose costs to food producers and consumers that 
are not outweighed by positive health outcomes�
The primary purpose of this paper is to reevaluate the 
data  published  in  the  Health  Canada  risk  assessment 
(Kuiper-Goodman et al�, 2010) and assess risk on a life-
time basis rather than individual age strata� This review 
was accomplished by evaluating the results of exposure 
assessments for OTA in food using data from Canada and 
by comparing these exposures to doses of OTA anticipated 
to  be  without  appreciable  risk�  Furthermore,  given  the 
disagreement  among  different  regulatory  agencies  on 
the mechanisms of carcinogenic activity of OTA, a critical 
review of the genotoxic potential of OTA was undertaken� 
It is well understood that OTA is very stable and resilient to 
primary and further food processing such as grain milling 
and baking� Grain milling results in a redistribution of OTA 
among the milled grain fractions such that some fractions 
exhibit lower OTA levels whereas others exhibit higher lev-
els than present in the unprocessed grain� We have there-
fore also reviewed the assumptions regarding processing 
factors that were incorporated into the risk assessment�
A  secondary  objective  is  to  review  the  need  for,  and 
assumed efficacy of, maximum limits for OTA in selected 
foods that are currently proposed by Health Canada, based 
on our reevaluation of the Health Canada risk assessment�
Proposed OTA standards in Canada
Standards for OTA have been adopted by the European 
Union (EU) and proposed by the government of Canada� Risk assessment of dietary ochratoxin A  149
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The United States does not currently have standards for 
OTA� Proposed standards for Canada and the existing 
European Union standards are summarized in Table 1� 
Although Canada has not proposed standards for all of 
the same food groups for which there are EU standards, 
the proposed maximum limits are very similar�
The EU standards were adopted based on the 2006 
opinion of the Scientific Panel on Contaminants in Food 
(EFSA, 2006) and the tolerable weekly intake (TWI) of 
120 ng/kg body weight� The results of an assessment of 
dietary intake of OTA by the population of EU Member 
States conducted by Istituto Superiore di Sanità–Rome–
Italy was used to select numerical values for the maximum 
levels for the specific food commodities (EFSA, 2006)� The 
Canadian standards appear to be based in part on the EU 
standards and in part on the results of a Risk Assessment 
of OTA for all Age-sex Strata in a Market Economy com-
pleted by Health Canada (Kuiper-Goodman et al�, 2010)�
Hazard assessment
Toxicities  of  OTA  demonstrated  in  animal  studies 
include  nephrotoxicity,  teratogenicity,  carcinogenic-
ity,  and  immunosuppression;  however,  species  and 
gender-related  differences  in  sensitivity  have  been 
noted� Detailed discussions of OTA toxicity studies are 
provided elsewhere (Kuiper-Goodman and Scott, 1989; 
EFSA, 2006; JECFA, 2008; Ringot and Chango, 2010)� In 
a recent review, differences in the metabolism of OTA 
by various species is discussed as a factor contributing 
to species differences in sensitivity to OTA toxicity (Wu 
et  al�,  2011)�  OTA  is  subject  to  metabolism  by  several 
different pathways including hydrolysis, hydroxylation, 
lactone-opening,  and  conjugation,  yielding  numer-
ous different metabolites� The major metabolite in ani-
mals and humans is ochratoxin-alpha which is readily 
excreted and considered to be nontoxic (Wu et al�, 2011)� 
Several other metabolites of varying toxic potential have 
been identified in urine or feces of rats, both of which are 
important routes of excretion as OTA is metabolized by 
the kidneys, liver, and intestines� The rat is thus far the 
only species in which a lactone-opened form of OTA with 
higher toxicity as compared to OTA, has been identified� 
The  major  metabolite  in  pigs  from  the  hydroxylation 
pathway  is  4-(S)-hydroxyochratoxin  A,  whereas  4-(R)-
hydroxyochratoxin A is the primary hydroxyl metabolite 
in  rats  and  humans�  Another  metabolite  identified  as 
10-hydroxyochratoxin A has been found only in rabbits� 
Further study is needed to characterize the toxicity of the 
various metabolites and to clarify if differences in sen-
sitivities of animals to OTA is related predominantly to 
different metabolic profiles�
The lowest dose effect noted in animal studies was 
renal function changes in pigs, which occurred at a dose 
of 8 µg/kg body weight/day� The lowest observed-effect 
level of 8 µg/kg body weight/day was determined from 
a 90-day subchronic study, in groups of 6 to 11 pigs, in 
which renal enzyme changes, and changes in renal func-
tion were noted at all doses (Krogh et al�, 1974)� In a 
follow-up study (Krogh et al�, 1979), exposure of six pigs 
to approximately 40 µg/kg body weight/day for 2 years 
led to progressive nephropathy but not renal failure� One 
striking difference observed in the kinetics of OTA in the 
pig, which may explain this species greater sensitivity to 
OTA is provided by work of Hagelberg et al� (1989) who 
Table 1  Standards for ochratoxin A.
Food commodity
European Uniona 
maximum levels 
(µg/kg)
Canadab (proposed) 
maximum limits 
(ppb)
Unprocessed cereals/raw cereal grainsc 5 5
All products derived from unprocessed cereals, including processed cereal products and  
cereals intended for direct human consumption with exception of foods for infants and young 
children and foods for special dietary purposes
3  
Direct consumer grains (i.e., rice, oats, pearled barley)   3
Derived cereal products (flourd)   3
Derived cereal products (wheat bran)   7
Breakfast cereals   3
Grape juice (and as ingredients in other beverages) and related products (concentrated grape 
juice, grape nectar, grape must intended for human consumption)
2 2
Dried vine fruit (currants, raisins, sultanas) 10 10
Wine, fruit wine, aromatized wine, aromatized wine-based drinks and aromatized  
wine-product cocktails
2  
Roasted coffee beans and ground roasted coffee excluding soluble coffee 5  
Soluble coffee (instant coffee) 10  
Baby foods and processed cereal-based foods for infants and young children 0.5 0.5
Dietary foods for special medicinal purposes intended for infants 0.5 0.5
aCommission Regulation (EC) No 1881/2006 of 19 December 2006 (also includes spices and liquorice; Commission of the European 
Communities, 2006); bHealth Canada’s proposed Maximum Limits (Standards) for the Presence of the Mycotoxin Ochratoxin A in Foods 
in February 2009 (Health Canada, 2009)’; ctakes into consideration the reducing effect of processing or redistribution; dFor bread, pastries 
and other flour-based foods, the guidelines to pertain to the flour portion. In the future, based on further monitoring data, Health 
Canada may consider modifying these maximum limits (MLs), or introduce MLs for products not yet covered.150  L.A. Haighton et al.
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calculated  clearance  of  OTA  by  renal  filtration  using 
glomerular  filtration  rates  and  concentrations  of  free 
fractions of OTA in plasma� Most species (quail, mouse, 
rat, monkey, and man) have a calculated clearance in the 
range of 1 to 14%, which are all at least 10 fold lower than 
the 110% value in the pig (Hagelberg et al�, 1989)� Other 
species differences in toxicokinetics of OTA have been 
recently reviewed (Coronel et al�, 2010)�
At  higher  doses,  50  µg/kg/d,  OTA  also  caused  an 
increased incidence of kidney tumors in rat studies, which 
was particularly evident in male rats (National Toxicology 
Program [NTP], 1989)� The renal tumor results of the NTP 
study are provided in Table 2� The tumorigenic response 
occurred  at  doses  higher  than  those  associated  with 
effects in pigs, however cancer is considered a more sen-
sitive endpoint if associated with a nonthreshold mecha-
nism of action� The likely mechanism for renal tumors in 
rats was evaluated and the results are discussed below�
Risks of human health effects associated with OTA
In  contrast  to  the  animal  data,  evidence  from  human 
studies  to  demonstrate  adverse  effects  of  OTA  at  cur-
rent dietary exposures, is inadequate� Based on rodent 
and pig studies, it is reasonable to assume that OTA, at 
high-enough exposures, would cause similar toxicities in 
humans� However, no epidemiology studies have been 
identified  that  conclusively  link  OTA  from  the  diet  to 
adverse health effects in humans� Although several stud-
ies have implied that OTA may be responsible for a human 
condition called Balkan Endemic Nephropathy (BEN), 
and OTA was reported to be present in crops in higher 
concentrations in BEN-endemic areas compared to non-
endemic areas (Gluhovschi et al�, 2011), this association 
has not been proven, and recent research into BEN is 
increasingly implicating aristolochic acid as the etiologi-
cal agent� Aristolochic acids were just recently listed in 
the Twelfth Report on Carcinogens as substances known 
to  be  human  carcinogens  (NTP,  2011)�  Moreover,  the 
recent review on biomarkers of OTA exposure highlights 
the challenges of monitoring OTA exposure in humans, 
and the lack of correlation between dietary exposure and 
blood levels (Duarte et al�, 2011)�
BEN is a chronic degenerative kidney disease associ-
ated with a high incidence of upper urothelial cancer 
in  humans�  Upper  urothelial  cancer,  which  includes 
tumors of the ureter and bladder lining, is not the same 
tumor as noted in rat studies in which the renal tubule 
cells were the target cell type at high doses, but it is one 
of  the  primary  tumor  types  observed  in  humans  that 
have  consumed  supplements  containing  aristolochic 
acids, and in animal studies with aristolochic acids (NTP, 
2011)� It is noted that the inclusion of aristolochic acids 
in the Report on Carcinogens occurred after the Kuiper-
Goodman et al� (2010) risk assessment was published�
The endemic nature of BEN suggests that some humans 
have a genetic predisposition to developing the disease, 
which makes them susceptible to an etiological agent that 
is likely to be an environmental factor� Environmental 
factors that have been suggested as the possible etiologi-
cal agents include lead, cadmium, polycyclic aromatic 
hydrocarbons,  selenium  deficiency,  viruses,  OTA,  and 
aristolochic acid (Mally et al�, 2007)� Of these suggested 
agents, OTA and aristolochic acid were the most plau-
sible� However, more recent research favors aristolochic 
acid as the causative agent (Nedelko et al�, 2009; Slade 
et al�, 2009; Stefanovic and Polenakovic, 2009; Stefanovic 
et al�, 2009)� Earlier publications also proposed that aris-
tolochic acid and not OTA may be the causative agent in 
BEN (Cosyns et al�, 1994; Arlt et al�, 2007; Grollman et al�, 
2007)�
Aristolochic  acid  is  the  causative  agent  in  Chinese 
herb nephropathy (CHN) which has been renamed aris-
tolochic  acid  nephropathy  (AAN)�  The  morphological 
and clinical profiles of BEN and aristolochic acid neph-
ropathy are similar (Stefanovic and Polenakovic, 2009)� In 
contrast, the histological origin of the tumors associated 
with BEN (upper urothelial cancer) is not the same as 
that of the tumors observed in the OTA rat studies (renal 
Table 2  Numbers of rats with renal tumors in the 2-year gavage studies of ochratoxin A.
Site/Lesion
Male Female
Vehicle 
control
21 µg/kg 
(adjusted 
dose 15 µg/
kg/d)
70 µg/
kg(adjusted 
dose 50 µg/
kg/d)
210 µg/kg 
(adjusted 
dose 150 µg/
kg/d)
Vehicle 
control
21 µg/kg 
(adjusted 
dose 15 µg/
kg/d)
70 µg/kg 
(adjusted 
dose 50 µg/
kg/d)
210 µg/kg 
(adjusted dose  
150 µg/kg/d)
Number examined 50 51 51 50 50 51 50 50
Kidney tubule
Adenoma, solitary 1 1 5 10 0 0 1 3
Adenoma, multiple 0 0 1 0 0 0 0 2
Carcinoma, solitary 0 0 12 20 0 0 1 3
Carcinoma, bilateral/ 
multiple
0 0 4 10 0 0 0 0
Renal tubule cell 
adenomas and 
carcinoma combined
1 1 22 40 0 0 2 8
Metastatic renal 
carcinoma (all sites)
0 0 4 13 0 0 1 0
Source: Summarized from results reported in the NTP (1989) rat study.Risk assessment of dietary ochratoxin A  151
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tubule—outer strip of outer medulla; Mally et al�, 2007)� 
Also, OTA and aristolochic acid differentially alter the 
regulation of expression of vascular endothelial growth 
factor (VEGF) in porcine kidney epithelial cells, as well 
as activity of the transcription factors that regulate VEGF 
(Stachurska et al�, 2011)�
The source of exposure to aristolochic acid was sug-
gested  to  be  wheat  inadvertently  contaminated  with 
seeds from the plant Aristolochia clematitis (Grollman 
and Jelakovic, 2007)� A mechanism explaining the higher 
incidence  of  BEN-associated  cancers  in  the  Balkan 
region with aristolochic acid as the causative agent was 
proposed  by  Nedelko  et  al�  (2009)�  Following  the  dis-
covery of adenosine (A) to thymine (T) mutations in the 
p53 tumor suppressor gene of tumor DNA samples from 
BEN patients (Grollman et al�, 2007), further studies of 
aristolochic acid were conducted which demonstrated 
that aristolochic acid induced these A to T mutations in 
human p53 sequences in vitro� These particular p53 muta-
tion sites, which are rarely mutated in human cancers in 
general, are found in BEN patients (Nedelko et al�, 2009)� 
Slade et al� (2009) also reported finding aristolochic-DNA 
adducts and the A to T transversion p53 mutations in 
the tumor tissue from patients with BEN in Croatia and 
Bosnia� A literature search neither found in vitro stud-
ies  which  reported  OTA  induced  A  to  T  transversions 
nor other mutagenic responses in human p53; however, 
activation of p53 was reported to inhibit OTA-induced 
apoptosis in monkey and human kidney epithelial cells 
(Li et al�, 2011)�
OTA is less likely than aristolochic acid to induce A to T 
transversions in the p53 gene of BEN patients as it is a weak 
mutagen at best (Nedelko et al�, 2009), and the results of 
another  study  have  shown  that  hypoxanthine-guanine 
phosphoribosyl  transferase  (HPRT)  gene  base  substitu-
tions of mammalian cells exposed to OTA did not include 
A to T transversions, and were similar to the spontane-
ous mutation pattern (Palma et al�, 2007)� Following an 
international symposium in Zagreb, Croatia on BEN that 
was held in October 2006, Grollman and Jelakovic (2007) 
reported that the cardinal conclusion emerging from the 
meeting was that aristolochic acid, and not OTA, was the 
primary risk factor for BEN and associated upper urothelial 
cancer� However, clarification of the slower progression to 
end-stage renal disease, and longer cumulative period for 
the occurrence of urothelial cancer for BEN in comparison 
to AAN is still needed (Pfohl-Leszkowicz, 2009; Slade et al�, 
2009)� Thus, although both OTA and aristolochic acid have 
been demonstrated to nephrotoxic in animals, the specific 
pathology  of  BEN  and  associated  urothelial  cancers  in 
humans has been demonstrated to be more closely reflec-
tive of that induced by aristolochic acids�
Mechanisms of toxicological effects in 
animals
The mechanism by which OTA induces renal tumors in 
rats is uncertain� In the absence of definitive data, the 
approach for assessing the potential health hazards of 
OTA to humans differs among some regulatory agencies� 
Health Canada has taken the position that the mechanism 
is nonthreshold, a default position based largely on a find-
ing of equivocal genotoxic potential (Kuiper-Goodman 
et al�, 2010)� The European Food Safety Authority (EFSA) 
concluded that the mechanism for carcinogenic response 
of OTA was most likely threshold based, the significance 
being that low doses below the threshold dose would not 
be associated with a cancer risk (EFSA, 2006)�
The  lowest  dose  of  OTA  administered  to  male  and 
female F344 rats in the cancer bioassays (21 μg/kg body/
weight, administered by gavage 5 days per week) was not 
associated with an increased incidence of renal tumors 
(Table 2)� The incidence of renal tumors was also very 
low in the female mid-dose group� These data support a 
threshold-based mechanism�
Furthermore, a recent publication (Mantle and Nagy, 
2008) demonstrating binding of OTA to α-2u-globulin, a 
classical species- and gender-specific response of male 
rats, which may, at least partially, explain the uncom-
monly potent response of OTA in male rats in the NTP 
gavage study� This study, which included only a few ani-
mals and can be considered as a hypothesis generating 
study, nevertheless contributes to the data supporting a 
threshold-based mechanism of action�
Using exponential dose-response relationship model-
ing, the tumor data from the F344 rats in the NTP study 
and data from a study in Dark Agouti male rats fed OTA 
for 2 years (Mantle et al�, 2005) indicate that OTA is a 
threshold carcinogen (Mantle and Nagy, 2008)�
In recent studies with male Dark Agouti rats (20/group), 
the incidence of renal tumors was not increased following 
administration of 400 ppb OTA in the diet (~50 µg/kg body 
weight/day decreasing to 20 to 30 µg/kg body weight/day 
for adults) from 8 weeks of age to 2 years (Mantle, 2009)� 
Three  additional  groups  (20/group)  were  administered 
5 ppm OTA in the diet for various periods of time (3 months, 
6 months, and 9 months) after which OTA was discontinued 
and the animals observed over the course of their natural 
life� Three months of continuous exposure to 5 ppm OTA 
(doses ranging from 640 μg/kg/day at study commence-
ment and declining to 450 μg/kg at 3 months, according to 
growth) was not associated with an increased incidence of 
renal tumors or other obvious pathological changes at the 
end of the observation study period� In the groups of male 
rats administered 5 ppm OTA for 6 months, and 9 months, 
1 out of 20, and 4 out 20 rats, respectively, developed renal 
tumors before the end of the study� However, it should be 
noted that the number of animals per group was less than 
the number used in the NTP bioassay� Also, this study may 
have  benefited  by  the  inclusion  of  a  lifetime  treatment 
group for comparative purposes�
Mantle (2009) plotted the renal tumor incidence data 
from all recent rat studies with accumulative dose on a 
logarithmic scale, as per the approach of Waddell (2006)� 
Similar to the data for the NTP rat study evaluated by 
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for all strains� In addition to the NTP rat data, Mantle 
(2009) included results from studies in Fischer, Fischer/
Sprague-Dawley  cross,  Dark  Agouti,  and  Lewis  rats� 
Mantle (2009) concluded that the dietary studies dem-
onstrated a two fold higher threshold for carcinogenic 
effects, in comparison to that observed for the gavage 
NTP (1989) rat study� In addition, Mantle (2009) noted 
that under the 3-month exposure protocol followed by 
an exposure-free period for the rest of the animals’ life-
time, exceptionally high doses of OTA (i�e�, 450 to 650 μg/
kg/day) failed to elicit any evidence of a nephrocarcino-
genic effect in Dark Agouti rats� Likewise, Mantle and 
Kulinskaya (2010), in a study similar in design to Mantle 
et al� (2005), reported that administration of OTA in the 
diet of F344 rats at a dose of 50 μg/kg/day for 2 years 
resulted in the formation of unilateral renal carcinomas 
in 4 rats out of 34 included in the test group� Mantle and 
Kulinskaya (2010) concluded that the gavage mode of 
dosing in the NTP (1989) study likely optimized condi-
tions for tumor development, whereas dietary exposure 
is of more relevance to the human situation� Vettorazzi 
et al� (2011) recently reported that administration of OTA 
to fasted versus fed rats resulted in increased bioavail-
ability of OTA, and higher maximum observed concen-
trations in both kidney and liver, with adult male rats 
showing the greatest difference due to fasting� It is noted 
that these latter two studies were not published until after 
the Kuiper-Goodman et al� (2010) study�
The significantly higher kidney tumor incidence fol-
lowing OTA exposure has been observed in males versus 
females in both rats and mice� Proposed mechanisms for 
the gender difference in susceptibility have included dif-
ferences in OTA transporters in the kidney, differences in 
expression of cytochrome p450 enzymes involved in the 
metabolism of OTA, and the presence of α-2u-globulin in 
the adult male rat� Although a role for α-2u-globulin in the 
dramatic difference between male and female rat kidney 
tumor incidence was originally dismissed, recent stud-
ies have reevaluated this male rat-specific mechanism� 
Studies by Mantle and Nagy (2008) demonstrating OTA 
binding to α-2u-globulin, specific rapid delivery of OTA 
to the proximal tubule epithelium by the α-2u-globulin 
protein, and reexamination of the renal tumor histology 
from the NTP study support a contributory role of this 
protein in the high incidence of renal tumors in male rats 
(Mantle and Nagy, 2008)� The α-2u-globulin, which binds 
to OTA, is an androgen-dependent rat-specific protein� 
In addition to the NTP study with F344/N rats, male-
specific susceptibility to OTA-induced renal tumors has 
been observed in Dark Agouti rats (95% males with renal 
tumors compared to 3% females) and in Lewis rats (80% 
males; 25% females; Castegnaro et al�, 1998)�
The binding of OTA to α-2u-globulin results in rapid 
delivery of OTA to the kidney proximal tubule epithelia 
by α-2u-globulin in males, creating a much higher con-
centration of OTA at the target site, with greater toxic-
ity and nephropathy than would occur in females� The 
binding and removal of OTA by α-2u-globulin in male 
rats also results in a shorter elimination half-life for OTA 
than in female rats� Higher plasma OTA levels after dos-
ing have been observed in female compared to male rats 
of various strains including the Fischer/Sprague Dawley 
cross (Mantle, 2009), Fischer (Zepnik et al�, 2003), and 
Dark Agouti (Castegnaro et al�, 2006)� One explanation 
for this difference is that in males, binding of OTA to 
α-2u-globulin and rapid delivery of OTA to the kidney, 
increases the rate of elimination from the blood, lower-
ing the OTA levels in blood� Thus, although the females 
have higher blood concentrations and a longer half-life 
of OTA, they are less susceptible to OTA renal carcino-
genesis than males (Dietrich et al�, 2005) because of a 
lower concentration at the target site� The lower tumor 
incidence seen in male rats in response to continuous 
dietary  OTA  as  compared  to  intermittent  oral  gavage, 
despite higher doses given in the diet studies, may also 
be attributed to the fact that the gavage protocol would 
result in surges of OTA delivered to the tubule as com-
pared to lower but more constant levels presented from 
feed intake (Dietrich et al�, 2005)�
There appears to be no human equivalent of the male 
rat urinary globulins (Mantle and Nagy, 2008)� Therefore, 
these authors have stated that extrapolation from dose-
response  data  from  experimental  rat  renal  carcinoma 
for human risk assessment may be appropriate only for 
female rat data�
It is proposed that the rapid delivery of OTA to the 
kidney  proximal  tubule  epithelium  would  result  in  a 
concentrated surge of OTA, resulting in higher toxicity 
and nephropathy than would occur with slower release 
of OTA from plasma proteins in females or from OTA in 
the diet� Repeated rounds of high concentration surges of 
OTA and subsequent cell damage, repair, and compensa-
tory cell proliferation are proposed as the mechanism of 
tumor formation (O’Brien et al�, 2001; Dietrich et al�, 2005; 
Mantle, 2009)� This mechanism can explain the reduced 
tumor formation in females as compared to male rats, 
fewer tumors resulting from dietary exposure as compared 
to gavage despite higher doses delivered by diet (Mantle, 
2009), and the lack of subsequent tumor formation in rats 
fed high doses of OTA for short periods (Mantle, 2009)� 
These observations support a threshold mechanism for 
carcinogenicity of OTA (threshold corresponds to a dose 
of about 16,700 ng/kg body weight/day)�
Genotoxicity of OtA
Conclusions regarding the genotoxicity of OTA, which 
would help to address the question of mechanism, also 
are ambiguous�
There exists an extensive body of historical data with 
respect to the genetic toxicity of OTA� These data have 
been reviewed by the International Agency for Research 
on  Cancer  (IARC,  1993),  the  Joint  FAO/WHO  Expert 
Committee on Food Additives (JECFA, 2008), and others 
(Brambilla and Martelli, 2004) and briefly summarized 
below�  In  an  earlier  Health  Canada  risk  assessment Risk assessment of dietary ochratoxin A  153
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on  OTA  by  Kuiper-Goodman  and  Scott  (1989),  it  was 
concluded that the available data supported that OTA 
was not mutagenic, but that it was weakly genotoxic to 
mammalian cells based on single-strand breaks� It was 
noted  that,  although  there  was  no  general  agreement 
on the significance of single-strand breaks, the authors 
did consider these changes as indicating genotoxicity, 
as they were concluded to be the result of a deleterious 
interaction of OTA with the hereditary material of the cell 
(Kuiper-Goodman and Scott, 1989)�
In general, in the Ames assay, OTA has been shown 
to be inactive (i�e�, negative), both with and without the 
presence of an exogenous source of metabolic activation 
(e�g�, Wehner et al�, 1978; Bartsch et al�, 1980; Bendele 
et al�, 1985; Zeiger et al�, 1988; NTP, 1989; Wurgler et al�, 
1991; Zepnik et al�, 2001; Föllman and Lucas, 2003)�
The SOS spot test in Escherichia coli, when conducted 
at noncytotoxic concentrations, has also produced exclu-
sively negative results with OTA (Auffray and Butibonnes, 
1986;  Krivobok  et  al�,  1987;  Malaveille  et  al�,  1991)� 
Similarly, in mammalian cell assays such as the HPRT 
assay  in  V79  hamster  cells  (Bendele  et  al�,  1985)  and 
the  TK  L5178Y  mouse  lymphoma  assay  (Föllman  and 
Lucas, 2003), OTA has shown no evidence of mutagenic 
activity�
The results of in vitro studies that have assessed the 
potential  for  OTA  to  cause  DNA  single-strand  breaks, 
or other cytogenetic effects in mammalian cell lines are 
mixed, with both positive (Mori et al�, 1984; Creppy et al�, 
1985; Štětina and Votava, 1986; Manolova et al�, 1990; 
Ehrlich et al�, 2002; Ali et al�, 2010) and negative results 
(Cooray, 1984; Bendele et al�, 1985; Štětina and Votava, 
1986;  NTP,  1989)  reported�  Variable  results  have  been 
reported in the comet assays using in  vitro exposures 
(Ehrlich et al�, 2002; Lebrun et al�, 2006; Simaro-Doorten 
et  al�,  2006;  Arbillaga  et  al�,  2007;  Klarić  et  al�,  2010)� 
Likewise, inconsistent results have been reported in non-
standard in vitro cytogenetic assays (Föllman et al�, 1995; 
Degen et al�, 1997; Dopp et al�, 1999)�
As with the in vitro sister-chromatid exchange, DNA 
strand breakage, and cytogenetic assays, the available in 
vivo data are also difficult to interpret due to conflicting 
results or the use of high doses that cannot be extrapo-
lated  to  the  results  of  the  carcinogenicity  studies�  For 
example,  although  positive  results  were  reported  for 
chromosome aberrations in the mouse at doses of 1 μg/
kg body weight/day in the diet for up to 45 days (Bose 
and Sinha, 1994; Kumari and Sinha, 1994), only a weak, 
nonstatistically  significant  response  was  reported  in 
rats treated at up to 2,000 μg/kg body weight/day for 5 
days (Mally et al�, 2005a)� No sister-chromatid exchanges 
were noted in response to gavage treatment of Chinese 
hamsters at OTA doses of 25 to 400 mg/kg body weight 
(Bendele et al�, 1985)�
Zeljezić et al� (2006) reported the results of a study 
in which OTA was assessed for capacity to induce DNA 
damage in the rat kidney in an in vivo alkaline comet 
assay� The authors administered OTA to groups of five 
adult female Wistar rats by intraperitoneal injection, dis-
solved in Tris buffer, at doses of 0�5 mg/kg body weight/
day for either 7, 14, or 21 days� Tissue analysis revealed 
the presence of OTA at mean concentrations of 4�86, 7�52, 
and 7�85 µg/mL in plasma after the 7-, 14-, and 21-day 
treatments, respectively� Corresponding concentrations 
in kidney tissue were 0�87, 0�99, and 1�09 µg/g respec-
tively� At all treatment durations, the tail length, intensity, 
and tail moment were significantly increased relative to 
the controls� The highest tail was noted after 21 days of 
treatment� This study demonstrates genotoxic potential 
in  vivo,  following  intraperitoneal  OTA  administration� 
The oral route of exposure and lower doses would have 
more closely mirrored potential human exposures� Also, 
it would have been useful to have tested male animals as 
the tumorigenic response in the kidney is much stronger 
in males�
Recently,  Hibi  et  al�  (2011)  investigated  the  in  vivo 
mutagenicity of OTA in the kidney tissue of F344/NSlc-Tg 
(gpt delta) transgenic rats� These rats carry ~5 tandem cop-
ies of the transgene lambda EG10 per haploid genome� 
Point mutations in these reporter genes are identified 
by 6-thioguanine (gpt gene), whereas deletions in red/
gam genes are detected by Spi(-) selection� In an initial 
experiment, groups of four to five rats of each sex were 
treated with OTA by oral administration at a dietary dose 
of 5 ppm for either 4 or 13 weeks� Following treatment, the 
kidneys were harvested, a portion of which was used for 
histological assessment while the remainder was used for 
assessment of mutations in the reporter genes and mea-
surement of 8-OHdG levels� Although exposure for up to 
13 weeks reportedly induced karyomegaly and apoptosis 
in the outer stripe of the outer medulla, no effect on the 
mutation frequencies in the recovered gpt or red/gam 
genes was reported� A second experiment was conducted 
in males only that followed a similar protocol as the ini-
tial experiment, except for a 4-week only exposure and, 
instead of using whole kidney preparations, the kidney 
tissue  was  macroscopically  separated  into  cortex  and 
outer and inner medullae, prior to analysis� The mutation 
frequencies of the gpt gene in the cortex and inner and 
outer medullae were unaffected by OTA treatment� In con-
trast, the Spi− mutation (deletion mutations) frequencies 
from the outer medulla were significantly greater (about 
three  fold)  than  the  controls�  The  authors  considered 
this result of particular significance as the outer medulla 
contains the S3 segment of the proximal tubules, the site 
of tumor initiation� There were no changes to 8-OHdG 
levels in either experiment� Based on these results, the 
authors concluded that a genotoxic mode of action is 
likely, and that oxidative stress is not likely involved in 
OTA carcinogenesis� Although the study indicates that 
OTA is associated with deletion mutations in the target 
tissue, the potency of effect was low, especially in rela-
tion to effects reported in this assay for known genotoxic 
chemicals  such  as  N-nitrosopyrrolidine  and  amino-3-
methylimidazo[4,5-f]quinoline (Kanki et al�, 2005) and 
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tumors in rats at very low doses� Essentially, although the 
data reported by Hibi et al� (2011) indicate some potential 
for genotoxic activity under the conditions of the assay, 
the role of this activity in the induction of kidney tumors 
is unclear�
Given the extensive testing of OTA in various genotox-
icity batteries, including a number of nonstandard pro-
tocols and the use of high concentration and high-dose 
exposures, it is not surprising that the results of these 
studies are mixed� This may be partly due to chance and 
in some cases due to artifacts (i�e�, product formed dur-
ing  processing  or  due  to  methodology;  Brusick,  1986; 
Galloway et al�, 1991), differences in experimental pro-
tocols and cell lines, use of high versus low concentra-
tions and doses, or improper interpretation of the data 
(Green  and  Muriel,  1976)�  Although  genotoxic  activity 
was observed under some assay conditions the finding 
of conflicting results does not necessarily support that a 
substance that is associated with tumor development in 
animals is in fact a genotoxic carcinogen� Potent geno-
toxic carcinogens generally show patent activity in the 
Ames  assay  or  in  an  in  vitro  chromosome  aberration 
assays, as well as in in vivo studies� In addition, where 
DNA adducts drive the mutagenic response, adducts are 
found at very high levels, are persistent and show concor-
dance with the tumor data� In the case of OTA, the data 
are much less amenable to straightforward interpretation� 
The lack of activity of OTA in the Ames assay, despite its 
potent effects on kidney tumor development in rats, does 
seem to suggest that the primary mode of action may not 
involve a direct genotoxic mechanism� The Ames test is 
highly predictive of the activity of genotoxic carcinogens 
(Kirkland et al�, 2005)� A contributory role for genotoxic 
activity, however, cannot be dismissed out of hand�
DNA adduct formation
In a number of 32P-postlabelling studies, lesions detected 
have  been  interpreted  as  being  OTA-derived  DNA 
adducts  in  cells  or  cell-free  extract  from  animals  and 
humans  (Pfohl-Leszkowicz  et  al�,  1993;  Grosse  et  al�, 
1995; El Adlouni et al�, 2000), as well as in vivo in rodents 
(Pfohl-Leszkowicz et al�, 1991, 1993; Faucet et al�, 2004; 
Pfohl-Leszkowicz  and  Castegnaro,  2005;  Manderville, 
2005)� In these studies, however, the identity of the DNA 
adducts has not been clearly established and it is not 
known whether in fact the alleged DNA adducts actually 
contain the OTA moiety� Although an OTA-DNA standard 
(C8-OTA-dGMP  adduct)  has  been  characterized  and 
produced by photo-irradiation of OTA in the presence of 
2-deoxyguanosine (Faucet et al�, 2004) and reported to 
coelute with one of the spots in a 32P-post-labelling study 
in which rats were treated with OTA for 2 years (400 μg/
kg body weight thrice weekly) and pigs treated (20 μg/
kg body weight/day) for 3 weeks, this adduct could not 
be confirmed by subsequent  32P-postlabelling assays in 
the rat kidney in vivo following treatment at nephrocar-
cinogenic doses for 3 weeks, using stable isotope dilution 
LC-MS/MS  methods  providing  for  limits  of  detection 
in  the  range  of  3�5  dG-OTA  adducts/109  nucleotides 
(Delatour  et  al�,  2008)�  Mally  et  al�  (2005a)  also  failed 
to detect this specific DNA adduct in rats treated orally 
with OTA at up to 2000 μg/kg body weight/day, 5 days/
week, for 2 weeks� In a number of other studies, several 
groups of researchers have also failed to detect any evi-
dence  of  DNA  adduct  formation  in  vitro  and  in  vivo, 
in  some  cases  using  similar  doses  as  reported  in  the 
“positive” studies (Schlatter et al�, 1996; Gautier et al�, 
2001; Gross-Steinmeyer et al�, 2002; Mally et al�, 2004)� 
Recently, Mantle et al� (2010) performed an LC/MS anal-
ysis of adducts associated with the in vitro incubation of 
OTA with calf thymus DNA� On the chromatogram, the 
adduct  cochromatographed  with  synthesized  C-C8dG 
OTA� The MS analysis, based on the ions detected, was 
reported to demonstrate that the adduct formed with calf 
thymus DNA was in fact C-C8dg OTA� This adduct (syn-
thesized) also cochromatographed with spots detected 
from autoradiographic analysis of the  32P-post labeling 
chromatograms of DNA extracted from the kidneys of 
F344 and Dark Agouti rats administered ~6800 to 8300 μg 
OTA/kg body weight/day (50- to 100 fold in excess of the 
tumorigenic dose in the NTP study) on three consecutive 
days� These analyses do provide significant evidence for 
the presence of the C-C8dG OTA adduct in treated rats, 
but only at low levels (i�e�, 20–70/109 nucleotides)� Mantle 
et al� (2010) also noted several potential methodological 
issues in studies, discussed in the previous paragraph 
which  did  not  report  presence  of  OTA  DNA  adducts 
either in vitro or in vivo, which could have led to the lack 
of findings of DNA adducts� Although the recent work of 
Mantle et al� (2010) provides compelling evidence for the 
presence of low levels of DNA adducts in OTA-treated 
rats, these researchers acknowledged that the presence 
of DNA adducts does not preclude the possibility of a 
threshold-dependent mechanism of kidney tumor for-
mation� Moreover, the presence of DNA adducts at low 
levels does not necessarily lead to the conclusion that 
these adducts are directly involved in tumorigenesis�
Further evidence for the formation of DNA adducts in 
vivo was presented in Jennings-Gee et al� (2010)� These 
researchers assessed the ability of OTA to induce DNA 
adducts in the testes of developing mice in vivo given that 
testicular and renal tissue share a common embryonic 
origin�  In  this  study,  three  separate  experiments  were 
conducted: acute and subchronic gavage feeding, and 
transplacental studies� Following single gavage dosing to 
groups of three male BALB/c mice at 3�5, 7, 35, 70, 289, 
578, or 1,056 µg/kg body weight, Jennings-Gee et al� (2010) 
reported, by 32P-post-labelling analysis, dose-dependent 
increases in the incidence of C-C8dg OTA adducts (from 
<1 to about 6 to 8 adducts/109 nucleotides in each of kid-
ney and testicular tissues� Other types of DNA adducts 
were also reportedly observed� In the subchronic study, 
groups of five male mice were administered OTA in the 
feed for 4 weeks to provide daily doses of 0�5, 1�4, 8, and 
20  µg/kg  body  weight/day�  Jennings-Gee  et  al�  (2010) Risk assessment of dietary ochratoxin A  155
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reported the presence of adducts in these mice as well, 
however,  quantitative  data  were  not  presented�  In  the 
third experiment, 6- to 8-week-old pregnant Swiss mice 
were  administered  OTA  by  intraperitonial  administra-
tion on the 17th day of gestation at a dose of 2,500 µg/
kg body weight� DNA adducts were quantified in the kid-
neys and testes of male newborn mice and in male mice 
sacrificed 1 month after birth� Three adducts were identi-
fied in newborn pups� The main spot in the kidney comi-
grated with C-C8 dGMP-OTA� Mean levels of this adduct 
in the newborns was 5�2 and 4�2 per 109 nucleotides in 
the testis and kidney, respectively� Levels in 1-month-old 
mice were generally slightly higher, presumably due to 
suckling or release of OTA from protein binding during 
the  period  after  cessation  of  exposure�  Jennings-Gee 
et al� (2010) speculated that these results may support a 
role for OTA in the development of testicular cancer� This, 
however, has not been demonstrated in 2-year rodent 
carcinogenicity bioassays�
A  causative  role  of  DNA  adduct  formation  in  the 
induction of kidney tumors is difficult to ascertain given 
the inconsistencies in the data reported, and the discor-
dance of low adduct levels with a high potency for kidney 
tumors in the male rat�
First, doses used in several of the studies with rats 
and  mice  were  above  those  that  caused  carcinogenic 
responses in the 2-year studies (i�e�, ~170 to 2500 μg/kg 
body weight/day versus ~50 to 150 μg/kg body weight/
day in the NTP, 1989 rat study) and exceeded estimated 
human exposures by upwards of 1,000,000 fold (Turesky, 
2005)� As a result, even if the alleged presence of DNA 
adducts is verified, it is not possible to extrapolate their 
presence to a causative role in carcinogenicity studies as 
these high doses may well be associated with inhibition 
of protein synthesis, generation of reactive oxygen spe-
cies, alteration of gene transcription, cell signaling, and 
apoptotic processes (i�e�, any DNA adducts may be arti-
facts rather than a direct genotoxic effect)�
Second, the dose response of the reported DNA adduct 
formation is highly nonlinear� For example, in the studies 
of Pfohl-Leszkowicz et al� (1991, 1993) in which Swiss 
male mice were administered single doses of 600, 1,200, 
or 2,500 μg OTA/kg body weight, the same amounts of 
adducts were reported at the low and intermediate doses 
with a sharp increase at the highest dose where adducts, 
not specifically identified, were detected at a maximum 
of about 100 per 109 nucleotides at 48 to 72 h postdos-
ing� This was despite the fact that peak concentrations 
of OTA were detected in the plasma at ≤24 hours after 
treatment�
Third,  the  maximum  levels  of  DNA  adducts  found, 
even at the high doses used in some of the studies, are 
very low and not typical of genotoxic carcinogens that 
produce  bulky  DNA  adducts�  Also,  as  discussed  by 
Turesky (2005), the levels of DNA adducts reported in 
kidney samples from rats treated with OTA at 400 μg/
kg body weight/day for 2 years were low and variable 
in the range of <1 to 114 adducts/109 bases (Castegnaro 
et al�, 1998)� Genotoxic carcinogens often produce DNA 
adducts at levels 100 fold (i�e�, 1 to 10 adducts/107 bases), 
or more, greater� Consistent with this fact is the report 
of Schlatter et al� (1996) that following single treatment 
of F344 rats with 3H-labelled OTA at a dose of 210 μg/kg 
body weight (i�e�, the carcinogenic dose reported in the 
NTP, 1989 study), the covalent binding index (CBI) was 
calculated to be <0�25 for the kidney and <0�1 for the liver, 
with essentially no radioactivity detected in either organ� 
The CBI which is a measure of the DNA damage/dose 
is calculated as µmol bound chemical/mol DNA nucle-
otide/mmol  chemical  administered/kg  body  weight� 
As noted by Schlatter et al� (1996), if a direct genotoxic 
mechanism of action were operative, one would expect a 
CBI in excess of 1,000�
Finally, in the Castegnaro et al� (1998) study there was 
no clear correlation of the DNA adducts, which were not 
specifically identified as OTA adducts, with the incidence 
of renal tubular adenocarcinoma, and there appeared to 
be considerable overlap in the amounts of adducts pres-
ent in male and female rats, despite the greater sensitivity 
of the male rat to OTA (Turesky, 2005)� Also, as pointed 
out by Turesky (2005), the quantity of adducts reported 
in the kidney tissue of the 2-year study (Castegnaro et al�, 
1998) was lower than that reported in Swiss mice treated 
at 2,500 μg/kg body weight as a single dose, again despite 
the rat being clearly more sensitive to the nephrocarcino-
genic effects of OTA�
The inconsistencies between the results of the various 
studies are difficult to reconcile given the differences in 
the methods used to isolate the DNA from tissues, dif-
ferences  in  the  solvents  used  in  the  chromatography, 
experimental variation in the TLC plates, pH changes, 
enzymatic  methods  for  DNA  hydrolysis,  and  so  on� 
Beyond the conflicting nature of the data with respect 
to DNA adduct formation and the low levels at which 
any putative adducts are formed, there is also the issue 
of the relevance of DNA adducts to mutagenic and car-
cinogenic activity� The formation of DNA adducts per se 
does not lead to a conclusion of mutagenic activity� Only 
adducts that are made permanent, and which disrupt 
normal DNA replication, transcription, and translation 
processes can produce “mutagenic” effects and increase 
risk for cancer (Nestmann et al�, 1996)�
The debate surrounding the potential formation and 
presence of DNA adducts following exposure to OTA has 
been recently reviewed and its chronology summarized 
(Duarte  et  al�,  2011)�  Overall,  the  role,  if  any,  of  DNA 
adduct formation in the carcinogenic activity of OTA has 
yet to be elucidated� However, the low numbers of adducts 
formed, in relation to the potency of OTA, would seem to 
be at odds with these adducts playing a major role in the 
induction of the carcinogenic response in the rat kidney�
Nongenotoxic modes of action
A number of studies have been reported to provide evi-
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indicate the formation of DNA adducts as a direct geno-
toxic mechanism is not likely in the case of OTA (Marin-
Kuan et al�, 2006, 2008; Arbillaga et al�, 2007; Mantle and 
Nagy, 2008; Mosesso et al�, 2008)� Examples of these are 
discussed below�
Induction of oxidative stress
Several studies provide evidence for the involvement of 
oxidative stress in OTA-associated DNA damage in the 
kidneys and liver (Kamp et al�, 2005; Mally et al�, 2005a, 
2005b)� This research has shown that while no adducts 
were  associated  with  OTA  treatment,  analysis  of  liver 
and kidney tissue in a modified comet assay showed that 
inclusion  of  formamido-pyrimidine-DNA-glycosylase 
(Fpg), an enzyme known to convert oxidative DNA damage 
into strand breaks detectable in the comet assay, resulted 
in enhancement of the degree of DNA damage found� In 
fact, in the Kamp et al� (2005) study, which used lower 
doses of OTA (30, 100, and 300 μg/kg body weight/day by 
gavage for 4 weeks versus 250 to 2,000 μg/kg body weight/
day, 5 days/week for 2 weeks), no evidence of basic DNA 
damage was noted in the comet assay in the absence of 
Fpg� Total DNA damage was only increased in the pres-
ence of the enzyme allowing for detection of oxidative 
DNA damage� It is unlikely to be the sole mechanism due 
to the fact that Mally et al� (2005a) did find that treatment 
of F344 rats with OTA at up to 2,000 μg/kg body weight/
day was not specifically associated with overt evidence of 
lipid peroxidation or an increase in the numbers of 8-oxo-
7,8-dihydro-2 -deoxyguanosine (8-OH-dG) adducts, both 
of which are biomarkers of oxidative stress�
Palma et al� (2007) assessed OTA in the HPRT assay 
in Chinese hamster V79 cells and in the TK mouse lym-
phoma assay� In both assays, OTA was reportedly weakly 
mutagenic  independent  of  metabolic  activation�  This 
is in contrast to negative results previously reported in 
these assays (Bendele et al�, 1985; Föllman and Lucas, 
2003),  although  treatment  conditions  were  different 
(Palma et al�, 2007)� Although the response was weak, 
of note was the finding that the mutation patterns were 
similar  to  those  of  spontaneous  mutants�  This  would 
indicate that bulky DNA adducts did not form, as under 
these conditions, different mutations, beyond the spon-
taneous types, should have been detected� The authors 
suggested  that  a  slight  increase  in  spontaneous-type 
mutants may be related to an increase in endogenous 
oxidative metabolism (Palma et al�, 2007), although this 
has not been confirmed or refuted� It is also possible that 
there was only a selection for, or statistical enhancement 
of, spontaneous mutations rather than de novo mutation 
induction�
Arbillaga et al� (2007) reported on the results of an in 
vitro gene expression study in a human renal cell line 
(HK-2) which indicate that the genotoxicity associated 
with OTA is not due to a direct DNA-reactive mecha-
nism� In this study, the renal cell line was exposed to 
OTA at concentrations of 50 μM for 6 or 24 h and gene-
expression profiles subsequently analyzed� In addition, 
OTA was assessed for genotoxicity on the basis of the 
results of a comet assay conducted so as to detect oxida-
tive DNA damage� Also, the OTA-exposed renal cell line 
was assessed for the presence of intracellular reactive 
oxygen  species  (ROS)  by  the  dihydrodichlorofluores-
cein  oxidation  assay�  Cytotoxicity  was  also  assessed� 
The incubations resulted in slight cytotoxicity at 6 h and 
moderate to marked cytotoxicity at 24 h� Analysis of the 
gene-expression profile revealed upregulation of genes 
associated  with  mitochondrial  electron  transport  at 
6 h  and,  additionally,  genes  associated  with  oxidative 
stress conditions (e�g�, inflammation response, calcium 
regulation and complement and coagulation cascades) 
after  24 h�  At  both  time  points,  intracellular  ROS  and 
oxidative  DNA  damage  (comet  assay)  were  increased 
and were greater as the degree of cytotoxicity increased� 
Noteworthy was the lack of any finding of upregulation 
of genes associated with cellular processes involved with 
DNA damage (e�g�, apoptosis, cell cycle control), even at 
the 24-h exposure point� These data are all consistent 
with a mechanism of action not involving direct geno-
toxicity� Furthermore, these data also support a role of 
oxidative  stress/ROS  generation  in  the  “genotoxic” 
response of OTA� The reported presence of DNA adducts 
in  some  studies  may  represent  nonspecific  oxidative 
adducts (EFSA, 2006) which are formed indirectly due to 
oxidative stress or oxygen radical formation at the high-
dose levels employed in many of the studies (Mosesso 
et al�, 2008)�
Marin-Kuan et al� (2006) conducted a toxicogenomic 
study in which groups of male F344 rats were dosed 
with OTA (~100 μg/rat) for 7 days to 12 months� Gene-
expression profiles were assessed at various intervals� 
Tissue-specific  responses  were  observed  in  the  kid-
ney versus the liver� In the kidney, the expression of 
several genes known as markers of kidney injury and 
cell regeneration was significantly altered, either up or 
downregulated, by OTA� Of significance was the find-
ing that the expression of genes known to be involved 
in DNA synthesis and repair, or of genes induced as 
a result of DNA damage, was only marginally altered 
by OTA treatment� Also, expression of genes thought 
to be linked with programmed cell death (apoptosis) 
appeared to be little, if at all, affected by OTA treat-
ment� Alterations of gene expression indicating effects 
on calcium homeostasis were noted� This finding was 
consistent with the results in the human renal cell line 
reported by Arbillaga et al� (2007)� Interestingly, the 
genes assessed that were relevant to oxidative stress 
and xenobiotic metabolism were generally downregu-
lated by OTA treatment� The gene expression profiles 
of elements regulated by hepatocyte nuclear factor 4α 
(HNF4α) and nuclear factor-erythroid 2-related fac-
tor 2 (Nrf2) were reported to occur in the kidney, but 
not in the liver� Marin-Kuan et al� (2006) noted that a 
reduction in HNF4α may be associated with nephro-
carcinogenicity� Also, these researchers reported that 
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and antioxidant defense processes� Reduced activity/
output of these genes could well be associated with 
impairments  to  the  defense  mechanisms  in  kidney 
cells, resulting in chronic elevation of oxidative stress� 
Such oxidative stress could, theoretically, be involved 
in  the  carcinogenic  response  of  the  kidney  to  OTA 
(Marin-Kuan et al�, 2006; Cavin et al�, 2007)� Also, in 
their study, there were other observed changes in gene 
expression  which  support  an  epigenetic  rather  than 
a genotoxic mechanism of action (Marin-Kuan et al�, 
2006, 2008)� Cavin et al� (2007) also report that reduc-
tions in Nrf2-regulated genes noted in the Marin-Kuan 
et  al�  (2006)  study  were  associated  with  analogous 
expression of proteins under Nrf2 genetic/regulatory 
control; therefore, the results reported by Marin-Kuan 
et  al�  (2006)  are  likely  of  biological  significance�  In 
addition,  Cavin  et  al�  (2007)  reported  an  increased 
formation of oxidative DNA damage, as measured by 
the number of abasic sites, both in vitro (rat NRK kid-
ney cells) and in vivo (kidneys from OTA dosed rats), 
further implicating a role of oxidative stress/reduced 
antioxidant defense mechanisms in the effects of OTA 
on the kidney�
Additional epigenetic mechanisms
Several review articles (Schilter et al�, 2005; JECFA, 2008; 
Mally and Dekant, 2009) document a complex array of 
epigenetic  mechanisms  that  may  play  critical  roles  in 
the development of kidney tumors and DNA adducts in 
rodents treated with OTA�
Potential mechanisms by which OTA may induce indi-
rect genotoxic effects include the following: cell prolifera-
tion; alterations to cellular apoptosis (Zhang et al�, 2009); 
changes in gene expression (Adler et al�, 2009); disruption 
of cell cycle progression (Adler et al�, 2009); perturbation 
of mitosis (Rached et al�, 2006; Czakai et al�, 2011), altera-
tions to cell-cycle signal transduction; protein-synthesis 
inhibition;  mitochondrial  dysfunction;  and  activity  of 
mitogen-activated  protein  kinases  (MAPKs;  Mally  and 
Dekant, 2009)�
The complex nature of the epigenetic mechanism(s) 
that  appears  to  be  involved  in  OTA-associated  car-
cinogenicity, and likely in adduct formation as well, 
precludes  the  teasing  out  of  any  one  as  a  singular 
definitive  cause�  In  summary,  the  results  of  classi-
cal  Organisation  for  Economic  Co-operation  and 
Development-compliant type mutagenesis studies on 
OTA have been mixed� In standard Ames assays OTA is 
nonmutagenic, whereas in vitro studies with mamma-
lian cell lines have shown negative results or only weak 
evidence  of  mutagenic  effects�  In  vitro,  DNA  strand 
breaks have been recorded with OTA, however, frank 
clastogenic effects appear only associated with cyto-
toxicity� The lack of activity of OTA in the Ames assay is 
unusual for a genotoxic carcinogen or of DNA-adduct 
directed genotoxicity� Overall, the majority of evidence 
favors a non-DNA reactive mechanism(s) not involving 
classical genotoxic effects�
Dose response assessment
Doses  of  OTA,  or  exposure  limits,  determined  to  be 
without appreciable risk of adverse effects, have been 
derived  by  regulatory  agencies  and  authoritative 
bodies� These exposure limits vary by about five fold 
depending on whether the basis of the exposure limit 
is  the  lowest  observed  adverse-effect  level  (LOAEL) 
determined from the 90-day pig study (Krogh  et  al�, 
1974) or the tumor data determined from the NTP rat 
study (NTP, 1989) and assuming a nonthreshold mech-
anism�  Examples  of  recently  derived  exposure  limits 
representative of these two different methods are by 
the EFSA (2006) and Health Canada (Kuiper-Goodman 
et al�, 2010)�
EFSA (2006) concluded that the mechanism for carci-
nogenic response of OTA was most likely threshold based, 
the significance being that low doses below the threshold 
dose would not be associated with a cancer risk� A TWI 
of 120 ng/kg body was derived for OTA from the LOAEL 
of 8 µg/kg/day for renal toxicity in pigs by applying an 
uncertainty factor of 450 to account for toxicodynamic 
interspecies differences between the pig and human (2�5 
fold), kinetic differences based on the half-life of OTA (six 
fold), intraspecies variability (10 fold), and the use of a 
LOAEL instead of a NOAEL (three fold)� On a daily basis, 
the  TWI  would  correspond  to  approximately  17 ng/kg 
body weight/day�
Using an approach comparable to EFSA (2006), JECFA 
(2008)  derived  a  provisional  tolerable  weekly  intake 
(PTWI)  for  OTA  of  100 ng/kg  body  weight,  or  approxi-
mately 14 ng/kg body weight/day, based on the pig study�
Kuiper-Goodman et al� (2010) concluded that the geno-
toxic status of OTA is equivocal and recommended the 
default approach that OTA be regulated as a nonthresh-
old carcinogen� A negligible cancer-risk intake (NCRI), of 
4 ng/kg body weight/day, defined as the exposure associ-
ated with a risk level of 1:100,000 was derived for OTA� As 
the first step in calculating the NCRI, Kuiper-Goodman 
et al� (2010) determined the tumorigenic dose associated 
with a 5% increase in tumor incidence above background 
(TD05) using the multistage model� The tumor incidence 
data for the male rat from the NTP gavage study were used 
in the model� The resultant TD05 was adjusted downward 
from 27�4 to 19�6 µg OTA/kg body weight/day as exposure 
to OTA in the NTP study was by gavage on only 5 out of 
7 days (27�4 × 5/7 = 19�6)� The NCRI was then derived by 
dividing the TD05 by 5,000, which was considered repre-
sentative of linear extrapolation to zero exposure�
It could be argued that basing the TD05 on the gavage 
NTP study results for the male rat is overly conservative for 
two primary reasons: (i) there is a large disparity between 
renal tumor incidence data based on species and gender, 
which indicates that male rats may be unusually sensitive 
to OTA; (ii) the gavage administration of OTA has been 
demonstrated to be associated with a greater increased 
renal  tumor  incidence  than  that  observed  following 
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humans�  This  has  been  demonstrated  with  the  same 
doses of OTA given by gavage (as in NTP study) versus 
in the diet (mimicking human exposure; Miljkovic et al�, 
2003; Mantle et al�, 2005)�
Although OTA had previously been discounted as a 
classical  α-2u-globulin-associated  renal  carcinogen, 
recent research efforts have revisited this issue and dem-
onstrated that there may be a contributory role of α-2u-
globulin in the male tumor response to OTA (Mantle and 
Nagy, 2008)� As α-2u-globulin is not present in humans, 
deferring to a TD05 based on the female data, which would 
be the more representative model for human relevance, 
would result in a higher NCRI� Based on the renal tubule 
cell tumor incidence data for the female rat, the adjusted 
TD05 (0�05) could be expected to fall slightly above 50 μg/
kg body weight/day given the observed tumor incidence 
data� Thus, the adjusted NCRI (if TD05 is 50 μg/kg/day), 
would  be  greater  than  10 ng/kg  body  weight/day  (as 
opposed to 4 ng/kg body weight/day based on the male 
rat)�
As a side evaluation, Kuiper-Goodman et al� (2010) 
recalculated the tolerable daily intake (TDI) from the 
90-day pig study (Krogh et al�, 1974) using a different 
methodology than EFSA (2006)� Instead of using the 
LOAEL of 8 µg/kg body weight/day, which was associ-
ated with effects on renal enzymes and renal function, 
as  starting  dose  and  applying  an  uncertainty  factor 
of  three  [as  per  EFSA  (2006)  methodology],  Kuiper-
Goodman et al� (2010) derived a benchmark dose (BD10) 
of 1�56 μg/kg body weight/day from the pig study (Krogh 
et al�, 1974) for use as the starting dose� Both used an 
uncertainty  factor  of  10  for  intraspecies  differences� 
Kuiper-Goodman  et  al�  (2010)  applied  an  additional 
uncertainty factor of two to extrapolate the 90-day sub-
chronic study to a chronic study (this is a default that is 
consistent with other risk-assessment methodologies)� 
However, in other longer term pig studies, such as the 
follow-up study by Krogh et al� (1979), the exposure of 
pigs  to  approximately  40  µg/kg  body  weight/day  for 
up to 2 years led to progressive nephropathy but no 
renal failure (EFSA, 2006)� Hence, the changes in renal 
function occurring at the lower dose of 8 µg/kg body 
weight/day in the 90-day study would not have been 
expected to progress to renal failure should exposure 
have been continued� Thus, the additional uncertainty 
factor of two should not be necessary� The uncertainty 
factors used for total interspecies differences were 15 
and  25  for  EFSA  (2006)  and  Health  Canada,  respec-
tively� Both EFSA (2006) and Kuiper-Goodman et al� 
(2010)  adjusted  the  toxicokinetics  component  of  the 
uncertainty factor to account for differences in half-life 
as discussed below�
EFSA (2006) applied a total uncertainty factor of 450 
to the LOAEL (starting dose) of 8 μg/kg body weight/
day  to  obtain  a  TDI  of  17 ng/kg  body  weight/day, 
whereas Kuiper-Goodman et al� (2010) applied a total 
uncertainty factor of 500 to a starting dose of 1�56 μg/
kg body weight/day to obtain a TDI of 3 ng/kg body 
weight/day� However, use of differences in half-lives to 
increase the interspecies uncertainty factor to 25 (or to 
15, as was done by EFSA), is not fully justified� Given 
that OTA is highly protein bound in the plasma, there 
is  no  clear  evidence  that  a  longer  half-life  increases 
sensitivity, but that it could actually be an indication of 
the contrary� The best means of predicting differences 
between species remains to be elucidated� One area to 
investigate is whether or not the strength of binding to 
plasma protein, while increasing circulation time, may 
show an inverse relationship to toxicity, given the lack 
of residence time in target organs�
Use  of  only  the  half-life  to  adjust  the  interspecies 
uncertainty factor also is questionable since the human 
half-life  value  is  based  on  a  single  volunteer  and  an 
adjustment for percent protein binding of OTA was not 
likewise  considered�  The  amount  of  unbound  OTA  in 
human plasma was 0�02% compared to 0�1% for the pig� 
Simplistically, if both the half-life and plasma binding dif-
ferences were considered in calculating the uncertainty 
factor for the intraspecies difference between the pig and 
the human, the uncertainty factor would be only five, as 
per the following relationship:
Toxicodynamics (2.5 ); Toxicokinetics related to OTA 
half -
×
l life : human to pig (10 ); free
OTA:  human to pig [0.02%/0.
×
1 1% (0.2 )]
2.5 10 0.2 5.
×
=× ×=
 Assuming the other uncertainty factors discussed above 
(i�e�,  intraspecies,  LOAEL  or  no  observed  adverse-
effect level or Benchmark dose, subchronic to chronic) 
remained the same, use of five as the new interspecies 
uncertainty factor would result in TDI values of 53 ng/
kg  body  weight/day  and  15�6 ng/kg  body  weight/day, 
in  place  of  the  TDI  values  reported  by  EFSA  (2006) 
and  Kuiper-Goodman  et  al�  (2010),  respectively�  Also, 
although the conservative default in risk assessment is to 
assume that the human is the most sensitive species for 
any toxicant, there are no data for humans to suggest a 
greater sensitivity to OTA than for pigs�
Exposure assessment
Exposures to OTA were estimated by Kuiper-Goodman 
et  al�  (2010)  using  various  mathematical  models�  In 
an effort to account for the highly variable occurrence 
data and to provide more realistic estimates of expo-
sure, multiple methods of analysis were employed and 
compared� These included a partial probabilistic and 
a full probabilistic (Monte Carlo) approach, the latter 
which was further adjusted to examine usual exposure 
estimates�  Monte-Carlo  is  a  stochastic  mathematical 
modeling  approach  that  allows  aspects  of  variability 
and uncertainty to be considered in the estimation of 
exposure� In this case, two main approaches were used, 
first a “partial” probabilistic exposure assessment was 
used,  which  multiplied  distributions  of  “all  person” 
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data� The second approach was the “full” probabilistic 
exposure, which combined distributions of food-con-
sumption data with distributions of OTA in foods� The 
results were presented on the basis of age–sex strata for 
the mean and various percentiles of exposure (Kuiper-
Goodman et al�, 2010)� Confidence interval data (5th 
and 95th) also were presented� No “all ages” , or “total 
population” data were presented�
Various approaches to the input parameters and treat-
ment  of  the  exposure  models,  specific  to  the  present 
case of estimating exposure to OTA were used by Kuiper-
Goodman et al� (2010) and are outlined as follows:
Occurrence  data:  In  this  assessment,  Canadian  1� 
occurrence data for raw food commodities and vari-
ous finished foods gathered over the past decade were 
used�  OTA-occurrence  data  used  in  the  exposure 
assessment were available for 37 different food com-
modities or categories that are known to sometimes 
contain OTA� Some of these commodities were rice, 
breakfast  cereals  (including  corn,  multigrain,  oat, 
rice, and wheat-based cereals), infant cereal, pasta, 
raisins, wheat (hard, soft, and durum), oats, barley, 
and peas� Beverages included beer, wine, grape juice, 
and coffee (ground–regular and decaffeinated, and 
instant–regular and decaffeinated)�
Processing factors: To account for redistribution of  2� 
OTA during the milling process, processing factors 
were used to convert the concentration of OTA in the 
raw grain to the foods as processed�
Handling of censored data: Two methods were used  3� 
to  deal  with  occurrence  values  that  fell  below  the 
limits of detection/quantification, including a distri-
bution developed by the authors, and by using ½ the 
LOD or ½ the LOQ as appropriate�
Maximum Levels (ML): In Europe maximum levels  4� 
(ML) have been set for OTA in many food commodi-
ties, and these ML’s were also used in the exposure 
models� When the MLs were used in the models, OTA 
occurrence values above these levels were assigned 
values equal to these levels (“ML-modified distribu-
tion of occurrence�”)
Food consumption data: The age–sex strata refer to  5� 
representative  population  groupings  based  on  the 
reported ages and gender of the dietary recall survey 
respondents�  The  U�S�  Continuing  Survey  of  Food 
Intakes  by  Individuals  (CSFII)  food  intake  survey 
1994–1996 and 1998 (USDA, 2000), is the basis of the 
exposure  estimates,  and  includes  food  consump-
tion data from two nonconsecutive survey days for 
>20,000 persons, of all ages� Validation procedures 
were run to ensure these data were appropriate for 
Canada�
 The  full  probabilistic  usual  (P*P)  mean  and  90th  per-
centile exposures to OTA that were reported by Kuiper-
Goodman et al� (2010) are included in Table 3� The data 
were determined on a kg body-weight basis and were 
reported for all persons on an age–sex stratum�
A full probabilistic exposure involves a scenario in 
which both the intake of foods and levels of OTA are 
modeled  as  distributions�  These  distributions  are 
then employed in a Monte Carlo analysis in which an 
individuals’ daily exposure to OTA is estimated many 
times, with each estimate run known as an iteration� 
In this case Kuiper-Goodman et al� (2010)  ran  1,000 
iterations�
Along with the full probabilistic model of exposure, 
an adjustment was made to develop a “usual” model of 
exposure� This model was developed by the authors and 
based on adaption of previous “usual” exposure mod-
els developed for nutrients� The usual exposure model 
extrapolates exposure from a short-term survey (e�g�, 1 or 
2 days) to a longer, more usual expectation of exposure� 
For  the  usual  exposure  model,  both  the  “within”  and 
“between” components of variance need to be consid-
ered� In this case, a “one-day” model was chosen, where 
the food-intake data were selected from either of the two 
survey days in the CSFII data to increase the realism of 
the model�
Although the results presented in Table 3 are for “all 
persons,” the data are essentially the same as for eaters 
only (consumers of any potentially OTA-containing com-
modity), as for all age groups from 6 to 8 months up to 
71+ years, 97% to 100% of all persons included in the sur-
vey consumed at least one potentially OTA-containing 
commodity (are “eaters”; from the age range of 9 to 11 
months to 71+ years, between 99�4% to 100% are eaters)� 
For the earliest age groups of 0 to 2 months and 3 to 5 
months, the percentage of surveyed individuals that are 
eaters, are 43% and 74�5%, respectively� For the 1-year 
age group, out of 1,040 respondents, 1,035 (99�5%) were 
eaters with the majority, 1,021 respondents (98�6%) hav-
ing consumed foods that could potentially contain OTA 
on both survey days�
For  the  full  probabilistic-exposure  model,  during  a 
single iteration, the workings of the model are as follows� 
Based  on  the  underlying  food  intake  distributions  for 
each individual, the software selects one input per food 
group, similarly based on the underlying distributions 
for occurrence data, the software selects one value per 
food group per individual� These values were combined 
and  this  process  was  repeated  1,000  times,  producing 
an exposure distribution of 1,000 values per individual� 
These exposures per food group were summed across all 
food commodities consumed by that individual to pro-
duce their total estimated OTA exposure on that survey 
day�  This  process  was  repeated  for  the  entire  popula-
tion, which produced an overall exposure distribution� 
This distribution was broken down according to the age 
and sex of the individuals, and described by calculating 
certain distribution parameters (mean, 50th, 75th, 90th, 
and other percentiles of exposure)� The 2-day average 
of these overall results gave a rough estimate of chronic 
exposure�
In completing the exposure assessment, the following 
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Many  of  the  concentration  data  are  based  on  raw  •	
food commodities and it was necessary to apply a 
processing factor, to account for known redistribu-
tion of OTA during the milling process, to estimate 
concentrations  in  finished  products�  Assuming  a 
processing factor rather than basing the concentra-
tions on only finished foods introduces additional 
uncertainty into the process� The processing factors 
used to correct the data were very conservative as the 
actual analytical data for pasta contamination were 
lower  than  that  derived  using  the  data  for  durum 
wheat as a surrogate and the estimated processing 
factors of 0�82 or 0�64 for the upper-bound and lower-
bound estimate, respectively�
Food samples for which OTA was not detected were  •	
not assumed to contain zero OTA� Such samples were 
usually assigned a concentration value based on the 
lognormal distribution of known concentrations or 
based on half of the limit of detection/quantification� 
The first method was preferred as the latter method 
tends to overestimate the mean when the number of 
positive samples is small�
The correction of the 2-day survey data to represent  •	
“usual” intake or intake over significant time peri-
ods (i�e�, 3 months to 1 year) is originally based on 
statistical methods for determining nutrient intake� 
Although this procedure may be statistically correct, 
in practice, the amount of correction is generally in 
the range of two fold whereas the difference in food 
intake using longer time data (e�g�, up to 14-day data) 
suggests up to a 10-fold difference in the intake of 
foods that are not consumed on a daily basis�
 As stated by Kuiper-Goodman et al� (2010), mycotoxin 
concentrations within a particular food commodity can 
vary by several orders of magnitude� Therefore, the expo-
sure estimates for the upper percentiles (95th, 97�5th, and 
maybe even the 90th) are based on iterations that com-
bined the upper range of food consumption data and the 
highest contaminant estimates of the input ranges� These 
data may be useful for the assessment of acute health 
risks, but would not be reflective of chronic intakes as it 
is unrealistic to expect that the highest consumers would 
always eat the most contaminated foods� The exposure 
estimates at these percentiles should not be used for pre-
dicting health risks associated with chronic OTA expo-
sures� Likewise, OTA food standards if derived by taking 
into  consideration  the  results  of  Margin  of  Exposure 
calculations using exposures at these upper-bound per-
centiles, may be unnecessarily conservative�
Two  additional  studies  reporting  on  the  concen-
trations of OTA in foods sold in Canada were recently 
published (Bansal et al�, 2011; Tam et al�, 2011)� In the 
first study, 200 samples of rice including both domesti-
cally grown and imported samples were analyzed for 
the presence of OTA (Bansal et al�, 2011)� The average 
concentration of OTA in the rice samples over the 2 
years  studied  were  0�05  and  0�005 ng/g,  respectively� 
The  limit  of  detection  (LOD)  was  0�05 ng/g;  there-
fore, the estimated concentration in the second year 
of study was less than the LOD and the only sample 
above the LOD was an imported sample of rice with an 
OTA concentration of 0�49 ng OTA/g� All samples were 
below the proposed ML of 5 ng/g� In comparison, the 
mean occurrence value of OTA in rice reported in the 
Kuiper-Goodman  et  al�,  (2010)  exposure  assessment 
was 0�80 ng/g with no ML and 0�68 ng/g when positives 
above the European ML were set to the ML�
The  Tam  et  al�  (2011)  study  reported  results  from 
the Canadian Total Diet Study from foods collected in 
Quebec City in 2008 and from Calgary in 2009� This study 
involved the analysis of numerous different food products 
and composites for the presence of OTA� Although 73% of 
samples had levels of OTA above the LOD (which ranged 
from 0�001 ng/g 0�008 ng/g, depending on the food stuff), 
the highest measured OTA value from the Quebec city 
survey was a sample of raisins containing 2�3 ng OTA/g 
and the highest measured value from the Calgary survey 
was a sample of wheat flour containing 1�7 ng/g, both of 
which are below the proposed ML�
Risk characterization
Given  the  disagreement  between  agencies  as  to  what 
would constitute a dose of OTA that would be acceptable, 
for the purpose of this review, consumption estimates 
were compared directly to the pig LOAEL and the rat 
TD05� The average consumption estimates are considered 
representative  of  chronic  dietary  intakes  whereas  the 
90th-percentile  (p90)  estimates  may  be  more  compa-
rable to acute dietary intakes such as could occur with 
problematic climate or storage conditions� The margin of 
exposure (MoE) comparison by age group is provided in 
Table 3�
Dietary  OTA  exposures  at  the  mean  and  90th  per-
centile  are  three  to  four  orders  of  magnitude  below 
the LOAEL determined from the pig dietary study and 
the TD05 determined from the rat gavage cancer study� 
Furthermore, these estimates of exposure are considered 
to be conservative or worst case as much of the concen-
tration data was based on raw food commodities� This 
necessitated the assumption of a processing factor which 
introduces additional uncertainty�
The data provided by Kuiper-Goodman et al� (2010) 
also allow for calculation of the resultant theoretical 
reduction  in  risk  with  the  implementation  of  stan-
dards� Kuiper-Goodman et al� (2010) estimated what 
the intakes would have been if maximum levels (ML) 
from the European Commission (EC; Commission of 
the European Communities, 2006) had been in effect 
and consistently met in all foods during the data collec-
tion period� This was accomplished by using the EC ML 
as the maximum concentration for all of those samples 
that exceeded that level� The TD05 estimate was divided 
by the estimates of exposure to determine a MoE� A 
ratio equal to 5,000 was considered to correspond to a 
risk of developing renal cancer of 1:100,000� If the MoE Risk assessment of dietary ochratoxin A  161
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was less than 5,000, it was concluded that there was a 
high priority for risk reduction� The MoE calculation 
was used for individual life stages rather than for life-
time exposures with no adjustment for consideration 
of duration of exposure� An MoE of 2446 was reported 
at the 90th percentile all consumers intake for respon-
dents 1 year of age� When the EC ML was applied the 
MoE increased to 3289� Thus, if the MoE of 5,000 was 
associated with a risk level of 1-in-100,000, the MoE of 
2,446 would theoretically be associated with a risk level 
of 1-in-48,920� This would be the expected risk if the 
individual remained at the same weight as a 1-year-old 
for a lifetime (usually considered 70 years), and contin-
ued to eat the same diet as the 1-year-old for a lifetime� 
If EU maximum limits for OTA were adopted, the MoE 
of 3,289 would theoretically be associated with a risk 
level of 1-in-65,780, again if the individual remained 
the same weight, and ate the same diet as a 1-year-old 
for a lifetime�
For both the MoE values of 2,446 and 3,289, the risk 
level  is  much  less  than  the  estimated  lifetime  cancer 
risk associated with ingestion of drinking water contain-
ing arsenic, a known human carcinogen, at the Health 
Canada–adopted  Maximum  Acceptable  Concentration 
(MAC) of 10 μg/L (Health Canada, 2006)� The lifetime 
cancer risk levels for arsenic at the MAC range from 1 in 
33,333 to 1 in 2,564, depending on the tumor type� The 
risk level for a 1-year-old is not reported�
Although the arsenic cancer-risk levels at the MAC are 
above what Health Canada considers to be “essentially 
negligible” (i�e�, 1 in 100,000 to 1 in 1,000,000), Health 
Canada has justified adoption of the arsenic MAC as a 
risk-management decision as it exceeds the health-based 
guideline value� In accepting this MAC, Health Canada 
(2006) decided that it represents “the lowest level of arse-
nic in drinking water that can be technically achieved at 
reasonable  cost,  especially  for  smaller  public  systems 
and private wells�”
Similar consideration is not given to OTA which also 
is  a  natural  contaminant�  Given  the  vast  quantities  of 
foods that are produced and imported into Canada, it is 
probably impossible for the affected agriculture and food 
industries to be able to guarantee that all shipments to 
which proposed OTA standards would apply will meet 
the  proposed  standards�  The  concentration  data  that 
Kuiper-Goodman  et  al�  (2010)  used  in  their  exposure 
assessment,  support  that  the  majority  of  grains  pro-
duced  in  Canada  under  current  agricultural  practices, 
and foods marketed, have very low OTA levels� The com-
modity with the greatest number of samples exceeding 
the proposed standard was infant cereal (26 >ML out of 
296), however, this was more attributable to the standard 
for finished infant foods being 10 fold lower that the raw 
grain standards (0�5 ng/g versus 5 ng/g)� The infant food 
standard  would  appear  to  be  unnecessarily  stringent 
given the very short time that the population consumes 
such foods� Most children are consuming adult foods by 
age of 1 year� Also, a processing factor of 0�1 (reducing or 
redistribution effect) would be needed to obtain finished 
infant cereals from the proposed maximum limit for raw 
grains� In comparison, the lower bound processing fac-
tor selected by Kuiper-Goodman et al� (2010) for use in 
the exposure assessment was 0�64 (corresponds to a 36% 
reduction in levels of OTA in raw grain versus finished 
Table 3  Comparison of estimated dietary OTA exposures to LOAEL and TD05 for all persons (ng/kg bw/d).
Age Mean
MoE for LOAEL of 
8,000 ng/kg/day
MoE for TD05 of 
19,600 ng/kg/day p90
MoE for LOAEL of 
8,000 ng/kg/day
MoE for TD05 of 
19,600 ng/kg/day
0–2 months 2.22 3,604 8,829 6.07 1,318 3,229
3–5 months 1.93 4,145 10,155 5.18 1,544 3,784
6–8 months 2.45 3,265 8,000 5.88 1,361 3,333
9–11 months 3.45 2,319 5,681 7.43 1,077 2,638
1 year 4.38 1,826 4,475 8.66 924 2,263
2 years 4.36 1,835 4,495 7.88 1,015 2,487
3 years 4.22 1,896 4,645 7.81 1,024 2,510
4 years 3.96 2,020 4,949 7.16 1,117 2,737
5-6 years 3.66 2,186 5,355 6.77 1,182 2,895
7–11 years 2.6 3,077 7,538 4.72 1,695 4,153
12–18 years 1.76 4,545 11,136 3.25 2,462 6,031
19–30 years M 1.76 4,545 11,136 3.4 2,353 5,765
31–50 years M 1.62 4,938 12,099 3.06 2,614 6,405
51–70 years M 1.43 5,594 13,706 2.73 2,930 7,179
71+ years M 1.33 6,015 14,737 2.58 3,101 7,597
12–18 years F 1.41 5,674 13,901 2.53 3,162 7,747
19–30 years F 1.33 6,015 14,737 2.54 3,150 7,717
31–50 years F 1.33 6,015 14,737 2.54 3,150 7,717
51–70 years F 1.23 6,504 15,935 2.35 3,404 8,340
71+ years F 1.15 6,957 17,043 2.23 3,587 8,789
LOAEL = lowest observed adverse effect level; TD05 = tumorigenic dose associated with a 5% increase in tumor incidence above 
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foods)� This gap suggests that consistent compliance with 
the proposed ML of 0�5 ppb is not reasonably achievable� 
Up to 8�78% of finished commodities and up to 14�81% 
of raw commodities, based on survey data between 1993 
and  2006,  exceeded  the  ML  (Kuiper-Goodman  et  al�, 
2010)� It remains to be seen if future enforcement actions 
of  adopting  standards  would  include  destroying  these 
lots� If these percentages of samples exceeding the ML 
are representative of future out of compliance product/
commodities that reach the market and/or are discarded 
early in the process, the implications could be quite seri-
ous including forcing companies out of business or sub-
stantially reducing crop yields�
Derivation of lifetime MoE for OTA
The MoE is the difference between the dietary exposure 
and the dose in rats associated with a 5% incidence of 
tumors above background (incidence in control or non-
treated rats)� Thus, the larger the MoE, the greater the 
confidence that no adverse effects will occur�
Kuiper-Goodman et al� (2010) indicated that when the 
difference between the mean or 90th percentile intakes 
and TD05 equals 5,000, the risk of developing renal can-
cer is taken as 1:100,000� The NCRI is similar in concept 
to other exposure limits such as the no significant risk 
level (NSRL), of the California Environmental Protection 
Agency,  or  a  1  in  100,000  risk-specific  dose  (RsD) 
level based on a calculated slope factor, as per the U�S� 
Environmental Protection Agency (U�S� EPA) Integrated 
Risk Information System (IRIS) methodology� However, 
these other values are representative of a lifetime risk� 
Thus, a MoE < 5,000 for a single age group would not truly 
reflect  the  incidence  of  1:100,000  lifetime  cancer  risk 
above background�
There is an inverse relationship when discussing the 
MoE  and  lifetime  cancer  risk�  Hence,  the  greater  the 
MoE, the lower the cancer risk�
The approach of applying of a factor of 5,000 to the 
TD05 to estimate the NCRI is discussed in greater detail 
in  Kuiper-Goodman  (2004)�  Two  additional  important 
points made in Kuiper-Goodman (2004), one of which 
was applied to this assessment and one that was not, are 
highlighted below:
This “approach can also be used for those threshold   
carcinogens  for  which  there  is  some  uncertainty   
regarding the mode of action (threshold versus non-
threshold, e�g� Ochratoxin A)”
  The “factor of 5000 can be decreased when addi-
tional biological information on the mode of action   
or quantitative aspects relating to human relevance 
indicate less concern” �
Kuiper-Goodman  et  al�  (2010)  did  not  present  the 
MoE for total population lifetime risks, but rather used a 
lifetime exposure limit for short-term exposures during 
specific periods of a lifetime� Using the Kuiper-Goodman 
et al� (2010) individual age group MoE values, we have 
extrapolated  lifetime  cancer  risks,  as  summarized  in 
Table 4, for OTA in rice and in hot oatmeal, and total 
population 90th-percentile intakes� The lifetime MoE for 
each category is calculated by multiplying the number of 
years in each age group by the age-specific MoE, sum-
ming the resulting totals for all age groups and dividing 
the grand total by 70 years�
One of the first foods introduced to children is rice� 
Thus, using the Health Canada-generated MoE values 
for regular specific commodity eaters (RCE) of rice as 
an example, a lifetime MoE adjusted for duration of 
exposure over a 70-year lifetime has been estimated� A 
lifetime MoE also has been estimated for hot oatmeal 
regular eaters, which had the lowest reported MoEs, 
and for 90th percentile all-person exposures� It should 
be noted that although intakes can be determined for 
all age groups, Kuiper-Goodman et al� (2010) did not 
report results for ages 2 through 6� Thus, for the pur-
pose of determining the lifetime MoE analysis, MoEs 
for this age group have been assumed to be the same 
as the values for 1-year-olds� This is overly conservative 
as  body  weights  increase  significantly  between  ages 
one and seven� For the 51- to 70-year age group, also 
not reported, MoE values for the 31- to 50-age group 
were applied as OTA exposures presented by Kuiper-
Goodman et al� (2010) were lower for the older adult 
strata (51 to 70 years), than for the middle-aged strata 
(31 to 50 years)� The results of this analysis, as estimated 
lifetime MoEs, are provided in Table 4�
In  all  cases,  the  lifetime  MoE  (difference  between 
human exposure and the TD05) is greater than 5,000 (i�e�, 
cancer risk level is less than 1 in 100,000), even without 
adjusting the higher concentration data reported down-
ward to the EC ML�
Although the results for all commodities are for “all 
persons,” the data are essentially the same as eaters only 
(consumers  of  any  potentially  OTA-containing  com-
modity), as the data in the publication indicate that for 
all age groups from 6 to 8 months up to 71+ years, 97% 
to 100% of all persons included in the survey consumed 
at least one potentially OTA-containing commodity (are 
“eaters”; from the age range of 9 to 11 months to 71+ 
years, between 99�4% to 100% are eaters)� For the earli-
est age groups of 0 to 2 months and 3 to 5 months, the 
percentage of surveyed individuals that are eaters, are 
43% and 74�5%, respectively� For the 1-year age group, 
out  of  1,040  respondents,  1,035  (99�5%)  were  eaters 
with  the  majority,  1,021  respondents  (98�6%)  having 
consumed foods that could potentially contain OTA on 
both survey days�
It should be noted that no data, such as plasma levels 
in infants, plasma half-lives for OTA or urinary clear-
ance rates are available to support greater sensitivity 
of children to the effects of OTA� In fact, the data from 
the  recent  feeding  study  conducted  with  male  Dark 
Agouti rats (20/group; Mantle, 2009) demonstrated that 
3  months  continuous  exposure  to  5 ppm  OTA  (doses 
ranging  from  640  μg/kg/day  at  commencement  and Risk assessment of dietary ochratoxin A  163
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declining to 450 μg/kg at 3 months inversely, accord-
ing  to  growth)  was  not  associated  with  an  increased 
incidence of renal tumors or other obvious pathologi-
cal changes at the end of the 2-year observation study 
period� In the groups of male rats administered 5 ppm 
OTA for 6 months, and 9 months, 1 out of 20, and 4 out 
20 rats, respectively, developed renal tumors before the 
end of the study� The incidence of renal tumors was not 
increased  in  Dark  Agouti  rats  administered  400  ppb 
OTA (~50 µg/kg body weight/day decreasing to 20 to 30 
µg/kg body weight/day for adults) from 8 weeks of age 
throughout natural life�
As the MoEs in Table 4 are based on the exposure 
data prior to correcting for EU ML standards, it can be 
inferred that the foods available in Canada, even with-
out adoption of proposed maximum limits, have been of 
acceptable quality in terms of dietary exposure to OTA�
However, as there is uncertainty regarding the sen-
sitivity  of  children  to  chemicals  and  exposures  are 
greater on a body-weight basis, risk-assessment prac-
tices have been developed to determine how early life 
exposures might impact lifetime cancer risks� The U�S� 
EPA Office of Research and Development has been at 
the forefront of risk assessment and cancer-evaluation 
methodology development for many years and it is an 
important resource for obtaining cancer potency data 
for specific chemicals determined to be human car-
cinogens� Potential human exposures may be very dif-
ferent than the route and dosing schedule employed in 
animal studies from which the slope factors have been 
derived� Thus, to account for intermittent or varying 
levels  of  exposure  experienced  by  humans,  the  U�S� 
EPA has recommended calculating a lifetime average 
daily  dose  (U�S�  EPA,  2005a)�  This  recommendation 
is  based  on  the  assumption  that  the  risk  associated 
with a high dose of a carcinogen received over a short 
period of time is equivalent to a low dose spread over a 
lifetime� This also implies that less than lifetime expo-
sure is associated with a linearly proportional reduc-
tion of the lifetime risk� Thus, assessment of less than 
lifetime human exposures has also employed the use 
of a lifetime average daily dose, which is adjusted to 
account for the number of years of exposure divided 
by 70 years (considered lifetime)� However, additional 
research has indicated that this reduction in risk may 
not be directly proportional due to susceptible popu-
lations and life stages (Murdoch et al�, 1992; Halmes 
et  al�,  2000)�  Consequently,  a  modifying  factor  may 
need to be applied to the cancer-risk estimate depend-
ing  on  the  circumstances  to  ensure  risks  are  not 
underestimated�
In the supplement to the guidance document (U�S� 
EPA,  2005b),  the  U�S�  EPA  calculated  age-dependent 
adjustment factors (ADAFs) to account for the possibil-
ity  that  children  are  more  susceptible  to  carcinogens� 
These factors, the values of which are indicated below, 
are applicable to carcinogens with a genotoxic mode of 
action  as  opposed  to  apparent  threshold  carcinogens 
such as OTA�
Children from birth to <2 years of age: ADAF = 10 •	
Children from 2 to <16 years of age: ADAF = 3 •	
16 years of age: ADAF = 1 (i�e�, no adjustment)� •	
 It is noted that the EPA approach is relevant to chemicals 
with a mutagenic mode of action (MoA) for carcinogen-
esis which is probably not the case for OTA�
Nevertheless, we repeated the calculation of lifetime 
MoEs from Table 4 to take into consideration the impact 
of early childhood sensitivity on lifetime risk� As the age 
breakdown in Table 4 does not correspond to the EPA age 
divisions for the application of ADAF, the calculations 
were adjusted accordingly (as described in the footnotes 
to the following table)� The results are summarized in 
Table 5�
Table 4  Calculation of lifetime MoE using Kuiper-Goodman et al. (2010) data for specific commodities and all commodities.
Age (years) No. of years
Rice MoE  
(no ML)
No. of 
years × MoE
Hot oatmeal  
(no ML)
No. 
years × MoE
All commodities 
(per age strata)  
p90 (no ML)
No. of 
years × MoE
0 to 6a 6 3,972 23,832 2,188 13,128 2,446 14,676
7 to 11b 5 6,588 32,940 3,918 19,590 4,360 21,800
12 to 18c 7 8,767 61,369 5,633 39,431 6,306 44,142
19 to 30d 12 9,611 115,332 5,821 69,852 6,399 76,788
31 to 50e 20 12,384 247,680 8,563 171,260 8,230 164,600
51 to 70f 20 12,384 247,680 8,563 171,260 8,230 164,600
Lifetime MoEg (sum of 
group MoE/70 years)
70   10,412   6,922   6,952
aMoE values are those reported in Kuiper-Goodman et al. (2010) for the 1 year age group with no ML.
bMoE values are those reported in Kuiper-Goodman et al. (2010) for the 7 to 11 year age group with no ML.
cMoE values are those reported in Kuiper-Goodman et al. (2010) for the 12 to 18 year age group with no ML.
dMoE values are those reported in Kuiper-Goodman et al. (2010) for the 19 to 30 year age group with no ML.
eMoE values are those reported in Kuiper-Goodman et al. (2010) for the 31 to 50 year age group with no ML.
fMoE values for the 51 to 70 year age group are the same as for the 31 to 50 year age group which is conservative since OTA exposures for 
the older adult strata are lower than the middle age strata reported in Kuiper-Goodman et al. (2010) with no ML.
gThe lifetime MoE is calculated by multiplying the number of years in each age group by the age-specific MoE, summing the resulting 
totals for all age groups and dividing the grand total by 70 years; the lifetime MoE was calculated by Cantox; other data were from the 
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The revised calculations to consider possible child-
hood sensitivity indicate that, although the application 
of  the  ADAF  reduced  the  lifetime  MoE,  the  resultant 
value was still greater than 5,000 under all scenarios, and 
hence, cancer risk is less that 1 in 100,000� Using the rela-
tionship of an MoE of 5,000 equating to 1 in 100,000 risk 
level, the lowest MoE in Table 5 of 6,288 (90th percentile 
all commodities), would correspond to a risk level of 1 in 
125,760, which is essentially negligible�
Summary
This  assessment  demonstrates  that  exposures  to  OTA 
from the diets of Canadians are three to four orders of 
magnitude below doses that have been associated with 
adverse effects in animals� Also, there is no adequate evi-
dence demonstrating that current dietary exposures to 
OTA may be associated with adverse effects in humans�
The results of the Kuiper-Goodman et al� (2010) risk 
assessment, when considered on a lifetime basis indicate 
that, even in the absence of OTA standards, exposures 
associated  with  historical  dietary  intake  would  not  be 
associated with a significant risk of adverse health effects� 
The lifetime MoE up to the 90th percentile based on his-
torical OTA-concentration data for foods considered to 
be the major sources of dietary exposure does not exceed 
5,000 even when early life sensitivity is considered; more-
over, there are considerable biological data to support 
that a safety factor lower than 5,000 could have been used 
for OTA in determination of proposed MLs�
These biological data supporting a lower safety factor 
than 5,000 for OTA include the following:
No evidence from human data that current expo- •	
sures  are  associated  with  adverse  effects;  recent 
data support that aristolochic acid and not OTA is 
the most likely environmental factor in BEN;
Recent  research  providing  support  for  many    •	
epigenetic  or  threshold-based  mechanisms  of 
action for OTA;
Rat studies demonstrate a threshold (no response at  •	
low doses);
Although  not  a  classical  •	 α-2u-globulin  renal  car-
cinogen, some involvement of this protein has been 
demonstrated which may explain the uncommonly 
potent response in male rats; α-2u-globulin is not 
present in humans;
OTA is negative in most genotoxicity assays includ- •	
ing those with highest specificity; a weak response, at 
most, was noted in others;
OTA is highly bound in plasma (based on data from  •	
one volunteer) with very low levels of free active OTA 
(greater plasma binding than in the pig);
The incidence of DNA adducts related to OTA is lower  •	
than expected for potent genotoxic carcinogens;
The dose response results noted for the male rat were  •	
determined to have a poor “goodness of fit” when fit-
ted to models used to calculate bench mark doses; 
the poorest was the multistage model which was the 
model used to calculate the TD05;
Table 5  Calculation of lifetime MoE using Kuiper-Goodman et al. (2010) data for specific commodities and all commodities with  
age-dependent adjustment factors (ADAF) applied.
Age (years) No. of years
Rice MoE  
(no ML)
No. of 
years × MoE
Hot oatmeal 
(no ML)
No. of 
years × MoE
All commodities 
p90 (no ML)
No. of 
years × MoE
0 to 2a 2 397 794 219 438 245 490
3 to 6b 4 1,324 5,296 729 2,917 815 3,261
7 to 11c 5 2,196 10,980 1,306 6,530 1,453 7,267
12 to 16d 5 2,922 14,612 1,878 9,388 2,102 10,510
17 to 18e 2 8,767 17,534 5,633 11,266 6,306 12,612
19 to 30f 12 9,611 115,332 5,821 69,852 6,399 76,788
31 to 50g 20 12,384 247,680 8,563 171,260 8,230 164,600
51 to 70h 20 12,384 247,680 8,563 171,260 8,230 164,600
Lifetime MoEi (sum of 
group MoE/70 years)
70   9,427   6,327   6,288
aMoE values are those reported in Kuiper-Goodman et al. (2010) for the 1 year age group with no ML but have been divided by a ADAF of 10.
bMoE values are those reported in Kuiper-Goodman et al. (2010) for the 1 year age group with no ML but have been divided by a ADAF of 3.
cMoE values are those reported in Kuiper-Goodman et al. (2010) for the 7 to 11 year age group with no ML but have been divided by a 
ADAF of 3.
dMoE values are those reported in Kuiper-Goodman et al. (2010) for the 12 to 18 year age group with no ML but have been divided by a 
ADAF of 3.
efMoE values for the 51 to 70 year age group are the same as for the 31 to 50 year age group which is conservative since OTA exposures for 
the older adult strata are lower than the middle age strata reported in Kuiper-Goodman et al. (2010) with no ML and no ADAF applied.
fMoE values are those reported in Kuiper-Goodman et al. (2010) for the 19 to 30 year age group with no ML and no ADAF.
gMoE values are those reported in Kuiper-Goodman et al. (2010) for the 31 to 50 year age group with no ML and no ADAF.
hMoE values for the 51 to 70 year age group are the same as for the 12 to 18 year age group which was the most conservative of the adult 
groups from Kuiper-Goodman et al. (2010) with no ML and no ADAF.
iThe lifetime MoE is calculated by multiplying the number of years in each age group by the age-specific MoE, summing the resulting 
totals for all age groups and dividing the grand total by 70 years; the lifetime MoE was calculated by Cantox; other data were from the 
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The rat study used to determine the TD •	 05 was a gav-
age study; this route of administration was demon-
strated to be associated with higher cancer risk in 
rats compared to that observed in rats when OTA was 
administered by the diet which is the route relevant 
to humans�
 Also,  DNA  repair,  apoptosis,  immunosurveillance 
mechanisms,  usually  discounted  in  risk  assessment, 
are effective particularly when the frequency of genetic 
events is low (related to weak potency of OTA as opposed 
to cellular responses to potent mutagens which would be 
overwhelming)�
This  reassessment  demonstrates  that  exposures  to 
OTA from the diets of Canadians are three to four orders 
of magnitude below doses that have been associated with 
adverse effects in animals and that there is no adequate 
evidence demonstrating that current dietary exposures to 
OTA may be associated with adverse effects in humans� 
Accordingly,  the  need  for  MLs  that  are  currently  pro-
posed for OTA in Canada, including infant cereals, has 
not been demonstrated�
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